
This J-Beauty Serum Has Completely Transformed My Skin
Just off the western coast of Japan, the Goto Islands have stunningly blue water, tree-covered hills, and a special plant: the camellia flower. Camellias look almost like a mono-colored kaleidoscope, their petals overlapping to create a perfect circle. These flowers aren't just beautiful, they're also functional, which is why Shiseido has whipped them into skin care. Most recently, these camellias are the star ingredient in Shiseido's new Ultimune Power Infusing Serum—which has made me a believer in the idea that flowers can transform your skin.
According to the Japanese skin care brand, the camellia's picturesque environment in the Goto Islands is also what makes them so nourishing. Though these islands are pretty, they also have a semi-harsh climate—they're prone to strong winds and whiplash weather changes. Camellias have adapted, making them resilient. (Hardy plants being used in skin care is nothing new—think about drought-resistant flowers like lavender or calendula.) In the new Ultimune serum, Shiseido used the same fermentation process as Japanese sake makers to boost the camellia's efficacy.
'Through the fermentation, we are able to increase the amino acid volume to 3.4 times higher,' a representative for Shiseido tells ELLE. In your skin, amino acids (the building blocks of proteins, to take you back to biology class) may work to help boost collagen, help repair wounds, and balance your skin's microbiome, according to a 2020 study in Amino Acids in Nutrition and Health.
The serum doesn't just use fermented camellia to bolster skin health—it also utilizes the entire plant, from the petals to the stems. The seed oil and extract promote collagen production and boost moisture, while the leaf and flower extracts tamp down inflammation. The serum also has other actives, like reishi mushroom and iris root, which work to protect the skin barrier.
Using this serum is a truly sensorial experience. First of all, I'm a sucker for anything red (it's kind of my color), so I already knew the bottle would have a place front-and-center on my vanity. The formula feels like it sinks into your skin instantly and leaves you with a dewy glow. I rarely finish serums—I have so many to test that I barely get halfway done with one before I'm onto the next. I used this serum every day for three months, but it still caught me off guard when I found that I was out of it. To me, actually finishing a bottle of anything is a testament to how good it is.
After using the Ultimune Power Infusing Serum consistently, I found that my normally dry skin looked much glowier and plumper, and I even felt like the fine lines and wrinkles on my face looked less pronounced. It mixes well with my routine and never pills under moisturizer, sunscreen, or makeup. In a rare move, I'm planning to open another bottle. It's one of the few products I've tried that has earned a permanent spot in my ever-changing rotation.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Elle
2 days ago
- Elle
Hailey Bieber Opens Up About Experiencing a Common Skin Condition—Here's How She Combats It
Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. Hailey Bieber is known for 'glazed donut' skin—dewy, poreless, and blemish-free. But as it turns out, she's just as susceptible to skin issues as the rest of us. This week, while in Europe with husband Justin Bieber to celebrate the release of his new album Swag, the Rhode founder took to her Instagram Story to share a close-up of her skin, saying that she was experiencing a 'perioral dermatitis flare.' For the uninitiated, perioral dermatitis is a rash. 'Think of perioral dermatitis as if acne and eczema had a baby—tiny red bumps like acne, paired with an itchy, rash-y vibe like eczema,' says Mona Gohara, MD, a dermatologist in Connecticut. 'Despite the name, it doesn't just show up around your mouth—it can sneak up around the nose, eyes, or even the chin.' In the photo Bieber shared, it looks like her perioral dermatitis is mainly visible on her chin and around her mouth. 'It always flares when I'm traveling a lot, sleep deprived, hormones, the wrong SPF, new products, stress,' she wrote. It makes sense—perioral dermatitis is an extremely common skin condition. According to Gohara, this rash can be brought on by common everyday products.'It's often triggered by too much of a good thing: heavy moisturizers, topical steroids, fluoride toothpaste, essential oils, or overuse of skincare actives like retinoids,' she says. 'Hormonal changes and stress can also stir the pot.' Gohara says that if you're experiencing a perioral dermatitis flare, your new mantra should be less is more. 'Think gentle cleanser, bland moisturizer, and no steroid creams,' she says. 'Dermatologists may prescribe a topical or oral antibiotic to help calm things down.' Bieber's pared-down perioral dermatitis skin care routine is perfect for helping calm irritation. When she's experiencing a bout, she keeps things 'so minimal.' To combat the condition, she forgoes cleanser altogether and instead rinses her face with water, then uses a prescription azelaic acid, hypochlorous acid, clindamycin (an antibiotic), and (naturally) Rhode Glazing Milk. Below, a more detailed look at the two over-the-counter products Bieber uses to help get her skin back to baseline. Bieber has previously shared on Instagram that she uses this hypochlorous acid spray from Tower 28. The ultra-gentle mist is naturally anti-inflammatory and antibacterial, which helps soothe skin and reduce redness. The Rhode Glazing Milk is a lightweight essence made with skin-strengthening ingredients like ceramides, which help repair your skin barrier and calm skin.


The Onion
3 days ago
- The Onion
Rabid RFK Jr. Bites Foreign Dignitary
WASHINGTON—In what may be their first apology issued for the behavior of a Cabinet member, White House officials reportedly apologized to a foreign dignitary Tuesday after the man was bitten by a rabid Robert F. Kennedy Jr. 'Sorry, sorry, that's just our health secretary—I don't know what's gotten into him!' senior aide Tasha Sturbridge said as Kennedy snarled and sank his teeth deep into the leg of Japanese envoy Haruto Tanaka, with eyewitnesses reporting a mixture of blood and frothed saliva ringing the secretary's mouth as his eyes rolled back in his head. 'Bobby, let go. Let go! Someone throw him some of his favorite zebra meat so he'll go for that instead. Mr. Tanaka, my apologies, but you should probably get that looked at. The secretary definitely isn't up to date on his shots.' At press time, reports con- firmed rabies cases were sky- rocketing in the D.C. area after Kennedy bolted out an open door of the White House.
Yahoo
3 days ago
- Yahoo
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, Germany), have recently invested to meet growing demand for antibody drug conjugates (ADCs) as targeted cancer treatments. The global ADC market was $10bn in 2023 and is anticipated to exceed $58bn by 2030 (Figure 1). According to leading data and analytics company GlobalData, ADCs are expected to lead as the largest growing group of medicines in the innovation pipeline for 2025, as the industry has seen an increase in deals to develop and manufacture ADCs. Last week, MilliporeSigma and Simtra BioPharma Solutions announced a five-year partnership to offer ADC manufacturing services to pharmaceutical companies. MilliporeSigma will offer bioconjugation manufacturing at its ADC production facility in St. Louis, Missouri, US, while Simtra will offer drug product formulation and fill-finish services. Both companies will cover the analytical work for ADC production. MilliporeSigma has a history of prioritising ADC production - the company invested $76m into its St. Louis facility in 2024, in addition to the $65m spent five years ago to build its ADC active pharmaceutical ingredient (API) site in Madison, Wisconsin, US. Last year, Simtra announced a $14m investment to expand its ADC conjugation and purification capabilities. Earlier this month, Carbogen AMCIS, an API manufacturer, along with an unnamed Japanese partner, shared that they would invest $31m to prepare two facilities in Switzerland for the commercial production of linkers by the first quarter (Q1) and Q3 2027. Another Swiss contract development and manufacturing organisation (CDMO), Lonza (Basel, Switzerland), also revealed plans to increase its ADC production capabilities last year, with the addition of two manufacturing suites to its Visp, Switzerland, site. Last month, BioNTech announced that it was preparing to file for US Food and Drug Administration (FDA) approval in second-line endometrial cancer later this year for its next-gen human epidermal growth factor receptor 2-targeted ADC, BNT323. Currently, the company is 'reliant on a China-based CDMO' to supply BNT323. However, the company shared plans to diversify its supply chain and decrease dependence on its Chinese partner by adding multiple BNT323 'supply nodes'. With impending tariffs on pharmaceuticals under the current government, there has been a rise in deals and investment to grow US manufacturing operations. Combined with the surge of ADC demand for oncology indications, clinical and commercial manufacturing contracts for ADCs are anticipated to increase. Although only 6% of the current ADC landscape is made up of marketed drugs, the ADC addressable market is expected to grow over the next decade, with 268 drugs currently in clinical stages of development (Figure 2). "ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio